Recent advances in nanosensors development for biomarker alpha-synuclein protein detection

Chauhan, Nidhi; Soni, Shringika; Jain, Utkarsh

doi:10.1016/j.procbio.2021.10.015

Cited by 9 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prepared sensor showed higher selectivity towards the analyte molecule, with a limit of detection of 3.5 × 10 −5 ng/mL. A more detailed summary of reported nanosensors for α-syn measurement is offered by Chauhan et al (2021) [ 294 ].…”

Section: Perspectives On Nanomedicine-based Therapies For Parkinson’s...mentioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

The complexity and overall burden of Parkinson’s disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

show abstract

Section: Perspectives On Nanomedicine-based Therapies For Parkinson’s...mentioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

show abstract

“…Recently, aptamers ( Apt ) have emerged as an area of interest and excellent alternatives to chromatography and electrophoresis for active identification [ 11 , 12 ]. They are oligonucleotide-based affinity probes that exhibit advantages of higher selectivity, stability, and sensitivity over antibodies [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Development of Nanomaterial-Modified Impedimetric Aptasensor—A Single-Step Strategy for 3,4-Methylenedioxymethylamphetamine Detection

et al. 2022

Self Cite

View full text Add to dashboard Cite

Developing rapid, sensitive detection methods for 3,4-Methylenedioxymethylamphetamine (MDMA) is crucial to reduce its current misuse in the world population. With that aim, we developed an aptamer-modified tin nanoparticle (SnNP)-based nanoarchitecture as an electrochemical sensor in this study. This platform exhibited a high electron transfer rate with enhanced conductivity arising from its large surface area in comparison to the bare electrode. This observation was explained by the 40-fold higher electroactive surface area of SnNPs@Au, which provided a large space for 1.0 μM AptMDMA (0.68 ± 0.36 × 1012 molecule/cm2) immobilization and yielded a significant electrochemical response in the presence of MDMA. Furthermore, the AptMDMA-modified SnNPs@Au sensing platform proved to be a simple yet ultrasensitive analytical device for MDMA detection in spiked biological and water samples. This novel electrochemical aptasensor showed good linearity in the range of 0.01–1.0 nM for MDMA (R2 = 0.97) with a limit of detection of 0.33 nM and a sensitivity of 0.54 ohm/nM. In addition, the device showed high accuracy and stability along with signal recoveries in the range of 92–96.7% (Relative Standard Deviation, RSD, 1.1–2.18%). In conclusion, the proposed aptasensor developed here is the first to combine SnNPs and aptamers for illicit compound detection, and it offers a reliable platform for recreational drug detection.

show abstract

Nano-mediated Strategies for Metal Ion–Induced Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

et al. 2022

View full text Add to dashboard Cite

Recent advances in nanosensors development for biomarker alpha-synuclein protein detection

Cited by 9 publications

References 81 publications

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Development of Nanomaterial-Modified Impedimetric Aptasensor—A Single-Step Strategy for 3,4-Methylenedioxymethylamphetamine Detection

Nano-mediated Strategies for Metal Ion–Induced Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

Contact Info

Product

Resources

About